

POST-COVID-19 HAEMATOLOGIC CHANGES: POTENTIAL MECHANISMS BEHIND INCREASED ANAEMIA RECOGNITION

Oskar Szymanski^{ORCID}, Magdalena Grzesiak^{ORCID}

University Medical Hospital in Wrocław, Poland

KEYWORDS: COVID-19; long COVID-19; anaemia; haemolytic anaemia

Disaster Emerg Med J

Dear Editor,
recently, I had the pleasure to read the publication by Acar et al. [1] in the Journal of Disaster and Emergency Medicine. The authors discuss the problem of anaemia detection rising between September 2020 and September 2023, specifically haemolytic anaemia and investigate any possible connections to the COVID-19 pandemic aftermath. The authors' conjectures appear to be in accordance with scientific findings concerning long COVID-19. Long COVID-19, also known as Post-Acute Sequelae of COVID-19 (PASC), is a condition where symptoms continue or appear after the initial phase of COVID-19 [2, 3]. The duration of these symptoms can extend for several weeks or even months following the resolution of the initial manifestations of the disease. The mentioned study period encompasses both the highest level of the pandemic's severity and its subsequent gradual decrease, making it a particularly intriguing timeframe for observing long-term COVID-19. With a prevalence rate ranging from 10% to as high as 30% among COVID-19 patients, this condition presents a substantial challenge for healthcare professionals and systems globally [4].

Existing literature has documented haematologic alterations in the erythroid system in individuals after

recovering from COVID-19, including anaemia, elevated mean corpuscular volume, and reduced haemoglobin levels [5]. Nevertheless, what mechanisms could be responsible for these alterations? While long COVID-19 does not specifically refer to a distinct disease, it encompasses a range of symptoms, including a vascular immune-mediated response and inflammation [4, 6].

Among the different ways a disease can manifest, the involvement of cytokine-mediated thromboinflammation is especially important in this situation. The presence of microvascular thrombosis, heightened atherosclerosis, and overall endothelial damage are potential factors that could contribute to the heightened awareness of anaemia caused by erythrocyte damage while passing through modified blood vessels. In addition, the literature also documents alterations in the structure of red blood cells in COVID-19 patients that continue for several months after being discharged from the hospital [7, 8]. These modified red blood cells display a noticeable physical characteristic - an elevated standard deviation in their level of flexibility, size, and volume. However, the red blood cells of patients who have recovered do not completely return to the condition of those in the healthy group. Furthermore, certain red blood cells

CORRESPONDING AUTHOR:

Oskar Szymanski, University Medical Hospital in Wrocław, 6/1 Prudnicka St., 50-503 Wrocław, Poland
phone: +48692734277; e-mail: osgiliat@wp.pl

Received: 25.08.2024; Accepted: 29.08.2024; Early publication date: 9.09.2024

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

exhibited diminished dimensions and irregular morphology, prompting researchers to hypothesize the presence of fragmented erythrocytes [7].

In addition to the changes in the shape of erythrocytes, COVID-19-induced oxidative stress also impacts the proteins and lipids present in the cell membrane. This leads to a decrease in the stability of the membrane and an increase in glycolysis within the erythrocyte [8]. Mature erythrocytes cannot produce new proteins, so these alterations remain unchanged throughout their lifespan, which may explain the prolonged symptoms. Structural protein damage and membrane lipid changes may make COVID-19 patients more likely to break down red blood cells. The damage caused by oxidative stress may explain this susceptibility. The altered shape and size of some red blood cells may increase spleen trapping and reduce lifespan due to damaged capillary walls.

On the other hand, erythrocytes that have undergone fewer changes and have not been removed from the bloodstream by the spleen are still susceptible to damage because their cell membrane is less stable, their ability to change shape is reduced, and they are believed to be more sensitive to oxidative stress. Patients with chronic fatigue syndrome (CFS), which is another manifestation of long-term COVID-19, have also shown a decrease in red blood cell (RBC) deformability [9]. Erythrocytes obtained from patients with CFS exhibited reduced membrane fluidity, modified surface charge on the plasma membrane, and elevated levels of reactive oxygen species.

Long-term COVID-19 causes haematologic changes. However, the exact development of these changes is complex and the role of different processes and modifications is unclear. This letter covered the main pathophysiological changes that may cause haematologic abnormalities. Additionally, the article hypothesizes mechanisms related to the increased identification of haemolytic anaemia in Acar et al. [1] article.

Article information and declarations Author contributions

The conceptualization and idea development for the study were carried out by Oskar Szymański. Magda-

lena Grzesiak was responsible for data preparation and conducting the literature review. The manuscript was written by Oskar Szymański.

Funding

None.

Acknowledgments

None.

Conflict of interest

All authors declare no conflict of interest.

REFERENCES:

1. Acar D, Karakuş N, Tekin F. Increased incidence of haemolytic anaemia in COVID-19 pandemic time? A cross-sectional study. *Disaster and Emergency Medicine Journal*. 2024, doi: [10.5603/demj.100867](https://doi.org/10.5603/demj.100867).
2. Jaroszewska A, Battsengel U, Zadorozna Z. REASSESSMENT OF THE UNDERLYING MECHANISMS THAT CONTRIBUTE TO THE NEUROLOGICAL DISORDERS LINKED TO LONG-TERM COVID-19. *Disaster and Emergency Medicine Journal*. 2024; 9(2): 129–130, doi: [10.5603/demj.100529](https://doi.org/10.5603/demj.100529).
3. Graban M, Pruc M, Chirico F, et al. Neurological implications of LONG-COVID-19 — current knowledge and the need for implementing remedies. *Disaster and Emergency Medicine Journal*. 2024; 9(1): 60–61, doi: [10.5603/demj.99169](https://doi.org/10.5603/demj.99169).
4. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol*. 2023; 21(3): 133–146, doi: [10.1038/s41579-022-00846-2](https://doi.org/10.1038/s41579-022-00846-2), indexed in Pubmed: [36639608](https://pubmed.ncbi.nlm.nih.gov/36639608/).
5. Lechuga GC, Morel CM, De-Simone SG. Hematological alterations associated with long COVID-19. *Front Physiol*. 2023; 14: 1203472, doi: [10.3389/fphys.2023.1203472](https://doi.org/10.3389/fphys.2023.1203472), indexed in Pubmed: [37565145](https://pubmed.ncbi.nlm.nih.gov/37565145/).
6. Zanini G, Selleri V, Roncati L, et al. Vascular „Long COVID”: A New Vessel Disease? *Angiology*. 2024; 75(1): 8–14, doi: [10.1177/00033197231153204](https://doi.org/10.1177/00033197231153204), indexed in Pubmed: [36652923](https://pubmed.ncbi.nlm.nih.gov/36652923/).
7. Kubánková M, Hohberger B, Hoffmanns J, et al. Physical phenotype of blood cells is altered in COVID-19. *Biophys J*. 2021; 120(14): 2838–2847, doi: [10.1016/j.bpj.2021.05.025](https://doi.org/10.1016/j.bpj.2021.05.025), indexed in Pubmed: [34087216](https://pubmed.ncbi.nlm.nih.gov/34087216/).
8. Thomas T, Stefanoni D, Dzieciatkowska M, et al. Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients. *J Proteome Res*. 2020; 19(11): 4455–4469, doi: [10.1021/acs.jproteome.0c00606](https://doi.org/10.1021/acs.jproteome.0c00606), indexed in Pubmed: [33103907](https://pubmed.ncbi.nlm.nih.gov/33103907/).
9. Saha A, Schmidt B, Wilhelmy J, et al. Erythrocyte Deformability As a Potential Biomarker for Chronic Fatigue Syndrome. *Blood*. 2018; 132(Supplement 1): 4874–4874, doi: [10.1182/blood-2018-99-117260](https://doi.org/10.1182/blood-2018-99-117260).